Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 2Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Psychiatric Rehabilitation 8Magnetic Resonance Spectroscopy 7Gemcitabine 7Capecitabine 7pembrolizumab 6Early Intervention, Educational 6Drug Therapy 6Cyclophosphamide 6Methods 5Therapeutics 4Specimen Handling 4Mental Status and Dementia Tests 4Docetaxel 4veliparib 3selpercatinib 3sargramostim 3palbociclib 3cediranib 3Trastuzumab 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Paclitaxel 3Oxaliplatin 3Irinotecan 3Fluorodeoxyglucose F18 3Counseling 3Cisplatin 3Carboplatin 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Canagliflozin × Breast × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡